EP2160189A2 - Préparation pour le traitement de la fourbure chez les équidés - Google Patents

Préparation pour le traitement de la fourbure chez les équidés

Info

Publication number
EP2160189A2
EP2160189A2 EP08758184A EP08758184A EP2160189A2 EP 2160189 A2 EP2160189 A2 EP 2160189A2 EP 08758184 A EP08758184 A EP 08758184A EP 08758184 A EP08758184 A EP 08758184A EP 2160189 A2 EP2160189 A2 EP 2160189A2
Authority
EP
European Patent Office
Prior art keywords
laminitis
allopurinol
treatment
pharmaceutical preparation
equidae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08758184A
Other languages
German (de)
English (en)
Inventor
Vincent Bachmann
Ingo Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BACHMANN, VINCENT
Original Assignee
Bachmann Vincent
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bachmann Vincent, Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica Inc filed Critical Bachmann Vincent
Publication of EP2160189A2 publication Critical patent/EP2160189A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention relates to a preparation for the treatment of laminitis, laminitis-associated pain and / or hoof-associated inflammation in equidae and in particular horses.
  • Laminitis or laminitis is a disease, especially in horses, and refers to an aseptic, i. Inflammation of the skin of the hoof skin not caused by infectious agents, whereby the hoof capsule may detach from the dermis.
  • Acute laminitis is an emergency and requires immediate treatment, which in extreme cases can lead to "flogging.”
  • Chronic laminitis can lead to coffin bone rotation.
  • the causes of laminitis are many and partly only speculative research. Basically, the causes can be summarized in two groups, namely as mechanically traumatic and toxic-chemical causes. All causes of laminitis have in common that they lead to a disturbance of the microcirculation of the blood in the area of the hoof skin. In mechanically traumatic laminitis, straining is caused by overloading the hoof and is mainly caused by long running on hard ground or by overloading a hoof, for example, after immobilization of the opposite leg. Even long stall phases can lead to a deer due to the disruption of the blood circulation triggered thereby. Among the toxic-chemical causes, feed rotation is the most widespread laminitis and is caused by incorrect feeding or the ingestion of poisonous plants.
  • the present invention is based on the observation that there are clinically similarities and similarities between the human disease of gout and equine equine hoofedness. Both in laminitis and in gout, the trigger may originate from the adrenal cortex and gonads. Interestingly, in both diseases it can be observed that it is a very complex metabolic disorder in both humans and horses. Nevertheless, there are pathogenetically significant differences between gout and laminitis.
  • the present invention relies on treatment successes achieved by the use according to the invention of the preparations / pharmaceutical preparations described below.
  • the invention therefore consists in the use of substances known from human medicine for the treatment of gout for the medicinal treatment of laminitis in equidae, in particular for the treatment of horses.
  • the use of a preparation containing at least allopurinol and / or cortisol and / or opium powder and / or prednisolone and / or prednisone is suitable for this purpose.
  • the present invention relates to the use of a preparation containing at least allopurinol and / or cortisol and / or opium powder and / or prednisolone and / or prednisone for the treatment of equine laminitis.
  • the present invention relates in particular to the use according to the invention of pharmaceutical preparations of: allopurinol and cortisol; Allopurinol and opium powder; Allopurinol and prednisolone; Allopurinol and prednisone; Cortisol and opium powder; Cortisol and prednisolone; Cortisol and prednisone; Opium powder and prednisolone; Opium powder and prednisone; Prednisolone and prednisone; Allopurinol, cortisol and opium powder; Allopurinol, cortisol and prednisolone; Allopurinol, cortisol and prednisolone; Allopurinol, cortisol and prednisone; Allopurinol, opium powder and prednisolone; Allopurinol, opium powder and prednisolone; Allopurino
  • the dosage of substances known from human medicine is extrapolated according to a projection on the respective body weight of the affected equid.
  • the present invention relates to the use of an allopurinol-containing preparation for the treatment of laminitis in equidae, in particular in horses.
  • Allopurinol inhibits the breakdown of purine to uric acid by inhibiting the enzyme xanthine oxidase and is therefore also referred to as ürikostatikum. It causes a lowering of the uric acid level in the blood, whereby deposits of uric acid in the tissue can be broken down and their new formation is made more difficult.
  • the increased accumulation of precursors of uric acid (xanthines) can be eliminated via the kidney (Ref.
  • allopurinol for the prevention of reperfusion damage in colic is also described in horses (Allen, 1993). However, this indication is fundamentally different from laminitis.
  • the postulated mechanism of action for the prevention of reperfusion damage is based on the interception of reactive oxygen radicals. Xanthine oxidase catalyzes the conversion of hypoxanthine to xanthine and finally uric acid. This reaction releases oxygen radicals that have direct cytotoxic effects. This is thus prevented by allopurinol and the active metabolite oxypurinol (cited in Mills et al., 1995).
  • Gout in humans is a deposit of uric acid crystals in joints.
  • the horse's hoof rubbing causes aseptic inflammation of the hoof skin. It is therefore unexpected and surprising that allopurinol, as well as other drugs used to treat gout, have an effect on laminitis.
  • a further effect of the present invention relates to the surprising finding that administration of allpurinol in equidae suffering from laminitis, in particular horses, leads to a rapid alleviation of pain and to a decrease in the inflammation associated with laminitis.
  • the present invention relates to the use of allopurinol for the treatment of laminitis-associated pain, particularly in equidae, such as horses.
  • the present invention relates to the use of allopurinol for the treatment of laminitis-associated inflammation, in particular in equidae, such as in horses.
  • Allopurinol and / or cortisol and / or opium powder and / or prednisolone and / or prednisone-containing preparations may be administered both orally, as well as subcutaneously, intravenously or intramuscularly.
  • the preferred dosage forms are oral or intravenous administration.
  • the present invention relates to oral, intravenous, subcutaneous or intramuscular preparations of allopurinol and / or cortisol and / or opium powder and / or prednisolone and / or prednisone for the treatment of equine laminitis, preferably in horses.
  • Particular preference is given to corresponding allopurinol containing preparations.
  • the corresponding oral, intravenous, subcutaneous or intramuscular preparations may also be used for the treatment of laminitis-associated inflammation and / or pain.
  • Allopurinol is particularly suitable for oral or intravenous use at a dose of 1 to 50 mg / kg, preferably in a dose of 2 to 20 mg / kg, more preferably in a dose of 5 mg / kg of body weight Equide. Accordingly, in a further aspect, the present invention relates to the use of an allopurinol-containing preparation for the treatment of laminitis, laminitis-associated inflammation and / or laminitis-associated pain in equidae in a dosage of 1 to 50 mg / kg body weight Equide.
  • the present invention relates to an allopurinol-containing preparation for the treatment of laminitis, hoof-lesioned inflammation and / or laminitis-associated pain in equidae, produced in a dosage of 1 to 50 mg allopurinol per kg body weight Equide.
  • corresponding allopurinol-containing preparations are prepared for oral, subcutaneous, intravenous or intramuscular administration.
  • the dosage mentioned here is preferably the daily dosage to be administered.
  • the duration of the treatment depends on the course of the disease. In general, a treatment period of 1 to 10 days appears effective. Preferably, the treatment is limited to 2 to 7 days, more preferably 3 to 4 days, preferably in the above-mentioned dosage. Accordingly, in a further aspect, the present invention relates to the use of preparations of allopurinol and / or cortisol and / or opium powder and / or prednisolone and / or prednisone for the treatment of laminitis, laminitis-associated pain or Laminitis-associated inflammation in equidae, wherein the corresponding preparation (s) is administered for 1 to 10 days, preferably 2 to 7 days, more preferably 3 to 4 days in one of the above mentioned doses.
  • the oral administration of allopurinol in horses with acute laminitis has the following effects: pain and inflammation go back after three days of treatment.
  • the existing lameness is also weakening.
  • the appetite of the horses increases again.
  • the condition of the horses is improved so that they can be treated with an orthopedic shoe fitting about one week after the start of treatment.
  • Treatment with Allopurinol does not allow this treatment until horses with severe pain can hardly be misted.
  • potassium has in cases where in the hoof b ven kritallome, no critical potassium levels can be detected in the blood, as potassium does not come back into the bloodstream. The veterinarian can draw in such cases no conclusions from the potassium values in the blood picture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'utilisation de principes actifs connus en médecine humaine pour le traitement de la goutte, pour assurer le traitement médicamenteux des fourbures chez les équidés, en particulier l'utilisation d'une préparation contenant au moins de l'allopurinol et/ou du cortisol et/ou de la poudre d'opium et/ou de la prednisolone et/ou de la prednisone.
EP08758184A 2007-06-19 2008-06-16 Préparation pour le traitement de la fourbure chez les équidés Withdrawn EP2160189A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028095A DE102007028095A1 (de) 2007-06-19 2007-06-19 Zubereitung zur Behandlung von Hufrehe bei Equiden
PCT/DE2008/000979 WO2008154898A2 (fr) 2007-06-19 2008-06-16 Préparation pour le traitement de la fourbure chez les équidés

Publications (1)

Publication Number Publication Date
EP2160189A2 true EP2160189A2 (fr) 2010-03-10

Family

ID=39789316

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08758184A Withdrawn EP2160189A2 (fr) 2007-06-19 2008-06-16 Préparation pour le traitement de la fourbure chez les équidés

Country Status (9)

Country Link
US (1) US20100190805A1 (fr)
EP (1) EP2160189A2 (fr)
CN (1) CN101808643B (fr)
AU (1) AU2008265318B2 (fr)
CA (1) CA2688251A1 (fr)
DE (2) DE102007028095A1 (fr)
MX (1) MX2009013076A (fr)
NZ (2) NZ602655A (fr)
WO (1) WO2008154898A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007028095A1 (de) 2007-06-19 2009-01-15 Bachmann, Vincent Zubereitung zur Behandlung von Hufrehe bei Equiden

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089813A (en) * 1958-06-02 1963-05-14 Ciba Geigy Corp Method for the treatment of ketosis in domestic and farm animals
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
CN100500155C (zh) * 2004-12-17 2009-06-17 范敏华 一种别嘌醇缓释片剂及其制备方法
WO2007045980A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
DE102007028095A1 (de) 2007-06-19 2009-01-15 Bachmann, Vincent Zubereitung zur Behandlung von Hufrehe bei Equiden

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008154898A2 *

Also Published As

Publication number Publication date
DE102007028095A1 (de) 2009-01-15
CN101808643B (zh) 2015-09-09
NZ581918A (en) 2012-10-26
DE102008034741A1 (de) 2010-01-28
MX2009013076A (es) 2010-03-04
CN101808643A (zh) 2010-08-18
US20100190805A1 (en) 2010-07-29
NZ602655A (en) 2013-12-20
AU2008265318B2 (en) 2013-11-14
CA2688251A1 (fr) 2008-12-24
WO2008154898A2 (fr) 2008-12-24
WO2008154898A3 (fr) 2010-03-18
AU2008265318A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
DE69833333T2 (de) Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
CN104039148A (zh) 组合als疗法
DE3390114T1 (de) Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung
EP1850830B1 (fr) Suppositoire destine a lier des composes oxygene reactifs dans le corps d'un homme ou d'un animal
DE60220512T2 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
DE60015098T2 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
DE2520978B2 (de) Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten
WO2008154898A2 (fr) Préparation pour le traitement de la fourbure chez les équidés
CN111514157A (zh) 组合物在制备兽用抗寄生虫病药物中的应用、兽用抗寄生虫病的透皮溶液及其制备方法
EP3675814A1 (fr) Composition pour le traitement topique de maladies inflammatoires de la peau et des muqueuses non provoquées par des micro-organismes
EP2522350B1 (fr) Utilisation de la combinaison de matière active constituée d'un dérivé de 1-diéthylaminoéthyle-3-chinoxaline-2-one et d'un oxystérol pour la rupture des résistances dans des traitements du cancer et pour l'augmentation de la capacité immunitaire lors de cancers, de maladies bactériennes ou virales, de maladies auto-immunes, d'effets de stress ou de pollution environnementale
WO2021259423A1 (fr) Utilisation d'antagonistes de co-enzyme pour ralentir le métabolisme
EP0670721B1 (fr) Medicament utilise dans le traitement et la prophylaxie des maladies osseuses et articulaires
EP0979083A2 (fr) Utilisation de 1-ar(alk)yl-imidazolin-2-one pour le traitement de l'angoisse et du stress
RU2684284C1 (ru) Способ терапевтического лечения острого нарушения мозгового кровообращения - инсульта по ишемическому типу в бассейне сонных артерий
DE2352618A1 (de) Arzneimittel zur behandlung des parkinsonismus
DE4435352C2 (de) Verwendung eines Arzneimittels zur Therapie von Aids
EP2509613A1 (fr) Composition pour le traitement de troubles gastro-intestinaux
JP2002173434A (ja) 抗アレルギー性組成物
Chaube et al. A novel ayurvedic anti diabetic medicine
DE3518559A1 (de) Neue verwendung von dihydroergotamin
DE60215051T2 (de) Zusammensetzung und verfahren zur behandlung chronischer allograft-abstossung
EP2863887B1 (fr) Émulsion pour une application pharmaceutique et procédé de préparation
DE102006002816A1 (de) Mittel zur Therapie und Prophylaxe von HIV
DE4308443C2 (de) Arzneimittel zur Behandlung von Retrovirusinfektionen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

R17D Deferred search report published (corrected)

Effective date: 20100318

17P Request for examination filed

Effective date: 20100920

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BACHMANN, VINCENT

Inventor name: LANG, INGO

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BACHMANN, VINCENT

17Q First examination report despatched

Effective date: 20141117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150103